Research programme: anticancer therapeutics - AtlasMedx
Latest Information Update: 19 Mar 2021
Price :
$50 *
At a glance
- Originator AtlasMedx
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Mar 2021 Research programme: anticancer therapeutics - AtlasMedx is available for licensing as of 09 Mar 2021. https://atlasmedx.com/partnering/
- 09 Mar 2021 Early research in Cancer in USA (unspecified route) (AtlasMedx pipeline, March 2021)